STOCK TITAN
  1. Home
  2. News
  3. CDNA

CareDx, Inc. - CDNA STOCK NEWS

Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.

CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.

CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.

The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.

CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.

Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.

News

CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
CareDx, Inc. (CDNA) will report financial results for Q4 and full year 2023 on February 28, 2024. The company focuses on healthcare solutions for transplant patients and caregivers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
conferences earnings
-
News

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) announces its participation in the 2024 Tandem Meetings to showcase its digital solutions and advancements in cellular therapy and transplant monitoring. The company will present data on AlloHeme and AlloCell at the event, highlighting their potential in treatment response monitoring and relapse detection post-transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
News

CareDx Issues Statement in Patent Infringement Case

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) has been found to have not infringed on Natera, Inc.'s patent 10,655,180 but was found to have infringed on patent 11,111,544. The District of Delaware jury awarded Natera damages of $83,679,521 in lost profits and $12,535,500 in past royalties for alleged infringement by AlloSure from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not impact patient or physician access to CareDx's current offerings, including AlloSure or AlloMap.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.53%
Tags
none
News

CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) is sponsoring the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium to highlight new real-world use cases using its testing and digital solutions for improved patient risk management. The company is focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. Leading transplant experts will demonstrate how CareDx's molecular testing services, digital solutions, and risk assessment tools can improve access and outcomes within transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
clinical trial
-
News

CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023

Rhea-AI Summary
CareDx, Inc. (CDNA) reported preliminary financial results for Q4 and full year 2023, with revenue expected to be in the range of $279-280 million, above guidance for fiscal year 2023. Testing Services patient results grew by 4%, while revenue for Patient and Digital Solutions and Products is expected to increase by 29% and 14% year-over-year, respectively. The company repurchased 2.8 million shares of common stock for $26 million and maintained a strong balance sheet with approximately $235 million in cash and cash equivalents and marketable securities, with no debt. However, revenue for the fourth quarter is expected to decrease by approximately 3% compared to the third quarter, driven by the impact of the Medicare Billing Article on Testing Services revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
earnings
-
News

CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) is expanding its reach by offering its Transplant Pharmacy services to National Foundation for Transplants (NFT) patient members to help them manage the complexity of post-transplant medication adherence. The collaboration aims to provide greater support in adhering to complex medication schedules for transplant patients, reducing out-of-pocket costs, and ensuring personalized care with regular touch points.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.81%
Tags
none
News

CareDx Reports Third Quarter 2023 Results

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) reported Q3 2023 financial results, including a 7% revenue increase to $67.2 million, raised revenue guidance to $274-278 million for 2023, and maintained a strong balance sheet with $268.2 million in cash and cash equivalents, and marketable securities, with no debt. The company also received Medicare coverage for HeartCare™ and AlloSure® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.9%
Tags
earnings
-
News

CareDx to Report Third Quarter 2023 Financial Results

Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) will report financial results for the third quarter 2023 on November 8th, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. Interested individuals can dial 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with Conference ID: CareDx. A live webcast will be available on CareDx's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
-
News

CareDx Announces CEO Transition

Rhea-AI Summary
CareDx, Inc. announces that Dr. Reginald Seeto will step down as CEO and President and transition to the role of Senior Advisor to the Chairperson. The company will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, CFO Abhishek Jain, and President of Patient and Testing Services Alexander Johnson. The Board has initiated a search for a permanent CEO. CareDx raises its 2023 revenue guidance to $274-278 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.98%
Tags
none
News

CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Rhea-AI Summary
CareDx, Inc. announces a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) to showcase its portfolio of HLA typing solutions and AlloSeq HCT for hematopoietic stem cell monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none

FAQ

What is the current stock price of CareDx (CDNA)?

The current stock price of CareDx (CDNA) is $20.61 as of December 20, 2024.

What is the market cap of CareDx (CDNA)?

The market cap of CareDx (CDNA) is approximately 1.1B.

What does CareDx, Inc. specialize in?

CareDx, Inc. specializes in precision medicine and surveillance management solutions aimed at improving the lives of organ transplant patients.

What is AlloSure®?

AlloSure® is a non-invasive blood test that measures allograft injury and detects donor-derived cell-free DNA (dd-cfDNA) to identify organ injury in kidney transplant patients.

Which organs do CareDx's products focus on?

CareDx's products focus on kidney, heart, and lung transplants.

Where does CareDx generate most of its revenue?

CareDx generates the majority of its revenue from the United States, primarily through its testing services.

What are some key products offered by CareDx?

Key products include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, all of which are dd-cfDNA solutions.

How does CareDx support transplant patients?

CareDx supports transplant patients by offering non-invasive diagnostic tests that help in monitoring and managing organ transplant health.

What technology does CareDx use in its diagnostics?

CareDx uses genomics and bioinformatics technology, specifically next-generation sequencing (NGS) to develop its diagnostic tests.

Does CareDx collaborate with other healthcare institutions?

Yes, CareDx partners with leading healthcare institutions to validate and implement their diagnostic solutions.

What kind of clinical evidence does CareDx generate?

CareDx generates high-quality clinical evidence through trials and registries to support the efficacy of its products.

What makes CareDx a leader in transplant diagnostics?

CareDx's combination of innovative diagnostic solutions, clinical evidence, and partnerships positions it as a leader in transplant diagnostics and surveillance.

Stock CDNA logo
CareDx, Inc.

Nasdaq:CDNA

CDNA Rankings

#2442 Ranked by Market Cap
N/A Ranked by Dividends

CDNA Stock Data

1.11B
51.79M
3.45%
96.05%
5.73%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BRISBANE